1. A method of minimizing inflammation at the injection site during subcutaneous administration of a macromolecule, comprising adding to the composition containing the macromolecule, from 5% to 20% polyvinylpyrrolidone (PVP) having a molecular weight in the range from 2000 to 54000 daltons. 2. The method of claim 1, wherein the macromolecule is a protein. The method of claim 2, wherein the protein is an antibody. The method of claim 3, wherein the antibody is a therapeutic antibody. The method of claim 3, wherein the antibody is a diagnostic antibody. The method of claim 3, wherein the antibody is an anti-CD20 antibody. The method according to claim 6, where the antibody contains an antibody variant A, B, C, D, F, G, H or I, as shown in Table 1.8. The method according to claim 6, where the antibody contains an amino acid sequence selected from the group consisting of SEQ ID NO: 1-15.9. The method of claim 6, wherein the antibody comprises a light chain variable domain of SEQ ID NO: 1 and a heavy chain variable domain of SEQ ID NO: 2.10. The method according to claim 6, where the antibody contains the variable domain of the light chain of SEQ ID NO: 3 and the variable domain of the heavy chain of SEQ ID NO: 4.11 The method according to claim 6, where the antibody contains the variable domain of the light chain of SEQ ID NO: 3 and the variable domain of heavy chains of SEQ ID NO: 5.12. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 6 and a full-length heavy chain of SEQ ID NO: 7.13. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 6 and a full-length heavy chain of SEQ ID NO: 15.14. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 9 and a full-length heavy chain of SEQ ID NO: 10.15. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 9 and a full-length heavy chain of SEQ ID NO: 11.16. The me
